Taking the Brakes off the Immune System to Fight Cancer

JCCC researchers Drs. Antoni Ribas and Edward Garon are reporting exciting treatment milestones for patients being treated with an experimental drug called MK-34751. Results show unprecedented durable responses and few adverse effects with MK-3475 in two types of cancer that historically have had very low survival rates. Click here to read the findings as reported at this past week's ASCO annual meeting in Chicago.

JCCC Member Resources

- Visit our membership info page to find out all of the benefits and privileges that are available to you as a JCCC member.

Clinical Trials at Your Fingertips

- Connect you and your patients with clinical trials at UCLA. Click here to learn all about how you can use any mobile device (including your smartphone) to access JCCC's clinical trials database.

Shared Resources at UCLA

- As a member you have access to several shared resources at JCCC, and over 70 additional shared resources at UCLA. Visit the Shared Resources page to learn more.

Update Your Member Profile

- Do you need a new member photo? Have new publications? Want to update your bio? Read the member profile guidelines to learn how.

Funding Opportunities

- Members can now access online a complete list of the latest research grant opportunities directly from the JCCC website.

Latest News

Researchers Deliver Double Dose of Lung Cancer Discoveries

Two JCCC scientists, Drs. Edward Garon and Jonathan Goldman, are reporting exciting dual discoveries in the treatment of non-small-cell lung cancer (NSCLC), the leading cause of cancer deaths in the United States. Two new experimental drugs, ramucirumab and CO-1868, developed for use in patients with advanced NSCLC, are showing great promise in UCLA clinical trials in a type of cancer that historically has had very poor outcomes. Read more >

Honor a Dad or Grad—Send an e-Card that Funds Research

JCCF eCards provide a meaningful way to deliver Father's Day or Graduation sentiments while supporting the JCCC's important work. Simply make an online gift of any amount to the JCCF and check the box for “Yes, I would like to send an eCard.” Next, select the design you prefer and complete your message. Click here to schedule your eCards today.

Drug Discovery Accelerates Immunotherapy for Cancer

UCLA researchers led by JCCC member Robert Prins have discovered a new histone deacetylase inhibitor drug called LBH589 that enhances an immune-based treatment for cancer. The treatment uses transplantation of T cells (in a process called T cell adoptive transfer) that are trained specifically to attack cancer cells transplanted into animals. Results found that LBH589 enhanced the activity of the T cells and of the immune system’s inflammatory response in mice. Read more >

Robotic-Assisted Prostate Surgery Offers Better Cancer Control
In pioneering research, a UCLA observational study comparing robotic-assisted surgery to traditional surgery for prostate cancer found that patients who had robotic surgery saw fewer instances of cancer cells remaining after surgery and less need of additional cancer treatments than patients who had traditional surgery. The study, led by JCCC member Dr. Jim Hu, was published in the journal European Urology.